在心力衰竭中使用Empagliflozin与保存的喷射分数:从随机试验到现实世界的证据
Sebastiaan Dhont1,2,3, Amrit Singh1, Bram Swinnen1
1Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium.
Acta cardiologica
|August 8, 2025
概括
恩帕格利弗洛辛有效地改善了老年心力衰竭患者的功能状况,并减少了老年患者的拥堵,其中包括保留喷射分数 (HFpEF) 的老年患者. 这项实践研究支持其在复杂患者群体中的应用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- 在EMPEROR-Preserved试验中证明了empagliflozin在心力衰竭中具有保存的喷射分数 (HFpEF) 的疗效.
- 老年人的现实数据,并发性HFpEF种群是有限的,需要进一步验证.
研究的目的:
- 评估empagliflozin在一个大型,现实世界的比利时HFpEF队列中的临床特征,耐受性和结果.
- 为了验证随机对照试验在多样化,老年患者群体中发现的结果.
主要方法:
- 一个回顾性,单中心的观察性研究包括577名HFpEF患者 (LVEF>50%) 开始每天服用10毫克的empagliflozin.
- 在2023年4月至2024年4月期间,从电子健康记录中收集了基线特征,临床参数,实验室值和结果的数据.
主要成果:
- 恩帕格利弗洛辛的使用显著改善了NYHA功能类 (56%至77%) 和减少了周围水 (26%至9%).
- 观察到静脉血压,心率,体重和BMI的适度降低,功能略有下降.
- 在平均16个月的随访期间,全因死亡率为6.9%,停药率低 (2.8%).
结论:
- 恩帕格利弗洛辛耐受性良好,在老年并发性HFpEF患者中改善了拥堵和功能状态.
- 这些现实发现支持HFpEF中empagliflozin随机试验结果的外部有效性.
相关概念视频
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
01:22Heart Failure Drugs: Diuretics
484
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
484
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:29Heart Failure II: Pathophysiology
41
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41